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The few studies published on angiogenesis in lymphoma have raised the question of whether or not microvessel density (MVD) is
associated with more aggressive disease and have reported the observation that in follicular lymphomas, vessels are mature rather
than immature. We investigated MVD and the vascular phenotype within follicular or diffuse large B-cell lymphomas, reactive nodes
and tonsils. Vascular phenotype was defined by the expression or loss of reactivity to the antibody LH39 (detecting the LH39 laminin
epitope of the basement membrane in mature vessels) and by detection of aVb3 (expressed on immature vessels). In reactive nodes
and in follicular lymphomas, MVD was higher in the paracortex than in germinal centres or in neoplastic follicles. However, in
neoplastic follicles an increase in aVb3-positive endothelium suggested the activation of an angiogenic pathway different from that
present in the reactive follicles. In large B-cell lymphomas, MVD was higher than in reactive and neoplastic follicles but lower than in
the reactive paracortex. The number of immature vessels (LH39 negative) and of aVb3-positive vessels was higher than in reactive
lymph nodes and follicular lymphoma suggesting that a switch to a different angiogenic pathway has occurred. Finally, we have
demonstrated that within reactive and neoplastic follicles vascular regression is occurring, perhaps constraining the growth of reactive
follicles alongside other phenomena such as apoptosis. Vascular regression was previously believed to occur in adults only in ovarian
and endometrial tissue. We conclude that different types of angiogenesis are present in follicular lymphomas and large B-cell
lymphomas. This has implications for possible future therapies.
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Evidence supporting a role for neoangiogenesis in haematological
malignancies has been found in lymphoid (Perez-Atayde et al,
1997; Kini et al, 1998; Veiga et al, 1998) and myeloid leukaemias
(Fiedler et al, 1997; Shami et al, 1998; Pruneri et al, 1999),
myeloproliferative disorders, myelodysplasia (Aguayo et al, 1998;
Pruneri et al, 1999) and myeloma (Vacca et al, 1994, 1999a; Raza
et al, 1999). In non-Hodgkin’s lymphomas, expression of
angiogenic factors in cell lines (Bellamy et al, 1999) and tissue
(Doussis-Anagnostopoulou et al, 1997; Foss et al, 1997; Turley et al,
1998) has been demonstrated.
Although these studies suggest a role for angiogenesis in
lymphomas several questions remain unanswered.
First, it is not clear whether high microvessel density (MVD) is
associated with more aggressive lymphomas. A group of authors
(Ribatti et al, 1996; Vacca et al, 1999b) reported that MVD is
higher in lymphomas than in reactive nodes and is higher in
aggressive than in indolent lymphomas. However, MVD in reactive
nodes has been found to be higher (Ridell and Norrby, 2001) or
comparable (Arias and Soares, 2000) to that observed in
lymphomas, including large cell lymphomas.
A second intriguing point is the observation by Hyjek et al
(Hyjek et al, 1999) that in follicular lymphomas, vessels have
mostly a mature phenotype (i.e. have pericytes) rather than an
immature as commonly reported in malignancies.
All these authors agree on two points: the neoplastic follicles in
follicular lymphoma appear to have fewer vessels than the
surrounding paracortex and the high-grade lymphomas. They also
noticed that staining for vascular markers highlights a similar
vascular distribution in reactive nodes and follicular lymphoma
while no reproducible vascular pattern is present in diffuse
lymphomas. The authors raised the question as to what this means
(Hyjek et al, 1999) but no explanation has yet been proposed.
The present study was aimed at answering these questions by
assessing both the MVD and the vascular phenotype of follicular
lymphoma, diffuse large B-cell lymphoma (as defined in the WHO
classification) (Jaffe et al, 2001) and reactive lymphoid tissues
(lymph node and tonsil). We wanted to compare MVD separately
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within the follicles (reactive and neoplastic) and in the paracortex
and to match the MVD data with the vascular phenotype. The aim
was to provide a more detailed evaluation of pathways of
angiogenesis in the neoplastic and physiological conditions, which
would be relevant to antivascular therapy strategies.
To distinguish between mature and immature vessels, two
markers were investigated. The first marker was the expression of
the LH39 epitope interacting with the antibody LH39, which is
expressed on the basal membrane of capillaries and small venules
in a variety of normal human tissues but is absent in small vessels
present in pyogenic granulomas or nonspecific oral ulceration
(Almeida et al, 1992a, b). These data have suggested that the
detection of LH39 staining discriminates between mature and
immature vessels, as supported by four further studies on oral
carcinomas (Almeida et al, 1992a), breast carcinomas (Kakolyris
et al, 1999) and lung cancer (Kakolyris et al, 1999; Passalidou et al,
2002).
The second marker examined is integrin aVb3 that has been
reported to be expressed on newly formed endothelium (Brooks
et al, 1994). Many authors have reported, on brain, skin, kidney
and lung, that endothelial cells express it to varying degrees (Rabb
et al, 1996; Navratil et al, 1997; Pazouki et al, 1997; Passalidou et al,
2002) although in one study of normal human breast tissue the
endothelium was negative for aVb3 (Gasparini et al, 1998). While
it is well established that endothelial expression of aVb3 is
essential for angiogenesis induced by basic fibroblastic growth
factor or tumour necrosis factor (Brooks et al, 1994; Friedlander
et al, 1995), it has also been found that it can be upregulated in
resting endothelium by a variety of biological stimuli (Tang et al,
1994) and that it is also present on resting endothelial cells
(Conforti et al, 1992). Study of this integrin remains important as
its expression identifies patients who could be eligible for clinical
trials with the humanized anti-aVb3 antibody Vitaxin (Gutheil
et al, 2000).
MATERIALS AND METHODS
Tissue samples
Frozen tissue samples were obtained from the Departments of
Histopathology at University College London and at the John
Radcliffe Hospital, Oxford. Samples were from 23 patients with
follicular non-Hodgkin’s lymphoma (of which five had focal
transformation to large cell lymphoma), 21 patients with large B-
cell non-Hodgkin’s lymphoma and 17 with reactive hyperplasia 12
lymph nodes and five tonsils. Fresh tissue was collected in the
theatre and frozen in liquid nitrogen. The diagnosis was performed
on routine formalin-fixed paraffin-embedded material with the
support of appropriate immunostainings according to the WHO
classification (Jaffe et al, 2001). One section for each staining was
evaluated for each patient for microvessels count. The section
contained usually all the lymph nodes.
Immunocytochemistry
The following antibodies were used: the anti-CD34 monoclonal
antibody QB10 (DAKO) staining endothelial cells , the antilamina
lucida antigen LH39 antibody and the anti-aVb3 antibody LM609
(Chemicon International, U.K.). Staining for CD3 and CD20 was
performed as well. We chose CD34 as endothelial marker as it does
not cross-react with lymphoid cells on frozen tissue, as CD31, and
stains a wider range of intratumour vessels than anti-Factor VIII
antibodies (Vermeulen et al, 1995).
All immunostainings were performed on frozen tissue sections.
In the single immunostainings, the primary antibody was
incubated for 1 h at room temperature. Labelling was performed
with an avidin– biotin peroxidase system (DAKO Duet). The
appropriate secondary antibody was applied for 35 min, after
which the Dako streptavidin –biotin complex was applied followed
by DAB solution to develop the staining reaction.
The double immunostaining was performed as follows using the
anti-CD34 and anti-LH39 antibodies. Firstly, the anti-LH39 anti-
body was incubated for 1 h at room temperature. Labelling was
performed with an avidin–biotin peroxidase labelling system
(DAKO Duet): the appropriate secondary antibody was applied for
35 min, after which the Dako streptavidin –biotin complex was
applied and the staining was developed by applying DAB solution.
After rinsing, the sections were incubated overnight with the
anti-CD34. After further rinsing sections were incubated with
rabbit-anti-mouse immunoglobulins and, finally, with APAAP
complexes.
All the cells showing staining were scored as positive,
independent of the staining intensity. Staining without the primary
antibody was routinely carried out as negative control.
Evaluation of vascularity
In the present study, microvessel is defined, according to the
classic definition of Weidner (1995) as ‘capillaries and venules’.
We regarded as a distinct countable microvessel any highlighted
endothelial cell or cell cluster clearly separated from adjacent
microvessels, tumour cells, normal cells and other connective
tissue elements according to the international consensus (Ver-
meulen et al, 1996).
In reactive tissue and in follicular lymphomas, the evaluation of
vascularity was performed separately for the follicles (either
reactive or neoplastic) and for the paracortical area. In follicular
lymphoma cases in which focal large cell lymphoma transforma-
tion was present (five cases), the area with a diffuse pattern was
scored separately. In diffuse large B-cell lymphomas only the
scoring of the neoplastic component was performed.
Evaluation of MVD We counted on each section the five vascular
hot spots (i.e. the five areas with the higher number of vessels).
Having put the vascular hot-spot area under a high-power field
( 400 objective), all the vessels present in the field were counted
and the value of the sum of the vessels counted in the five spots
was calculated.
Evaluation of vascular phenotype To evaluate the proportion of
mature vessels, at least 200 vessels were counted from each slide
on which double immunostaining for CD34 and LH39 had
been performed. If less than 200 vessels were present in the
section, they were all counted. The vascular maturation index
(VMI) defined by Kakolyris et al (1999) as the percentage of LH39/
CD34-positive vessels to the total of CD34-positive vessels was
calculated.
Similarly, an index was derived comparing vessels positive for
aVb3 to all the CD34-positive vessels. In this case, the staining was
performed on serial sections and the count for CD34 on a section
was related to the count for aVb3 on the same areas on the
following section. Also in this case, we counted at least 200 CD34-
positive vessels from each biopsy. If less than 200 vessels were
present, they were all counted. In this case, the index indicates the
percent of the vessels expressing aVb3.
Evaluation of vascular regression Vessels were scored as regres-
sing according to the criteria described by Holash et al (1999) on
rat experimental tumours: briefly, they performed double im-
munostaining for Smooth Muscle Actin and for Rat Endothelial
Cell Antigen. They classified a vessel as regressing when firstly
there was endothelial cell detachment followed by endothelial and
smooth muscle cell fragmentation. Their criteria were strictly
followed (if in any doubt, the vessels were not scored as
regressing). The only difference is that instead of looking at
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smooth muscle cells the vascular basal membrane was looked at
and identified by the expression of LH39 while we used CD34 as
human endothelial marker.
The number of regressing vessels was counted compared with
the total number of vessels. All the vessels were scored within the
follicles present on each section (either reactive or neoplastic) and
the vessels present in five randomly chosen high-power fields in
the interfollicular areas (reactive tissue and follicular lymphoma
cases) or in the areas of diffuse lymphoma.
Statistical analysis
Comparisons of MVD counts, number of mature vessels (LH39+)
and putative immature vessels (aVb3+) and comparison of
regressing vessels, between follicles and paracortex in reactive
hyperplasia and follicular lymphomas, were carried out using
paired sample t-tests since all vessel values were referring to the
same sample. There were 17 reactive samples from nodes and
tonsils, and 23 follicular lymphomas. All comparisons gave a
significant P-value at the 95% significance level (Tables 1 and 4).
Independent sample t-tests were used for similar comparisons
between reactive lymphoid tissue, follicular lymphomas and
diffuse large B-cell lymphomas. The P-values are given in Tables
2 and 4.
RESULTS
Microvessel density (MVD)
Results of MVD scoring are shown in Tables 1 and 2. MVD was
lower in the follicles, both reactive (germinal centres) and
neoplastic follicles, than in the paracortex (Table 1). There was
no difference between the MVD in reactive follicles (germinal
centres) and neoplastic follicles or between paracortical areas in
reactive tissue and in follicular lymphomas (Table 2). MVD in
diffuse large cell lymphomas was higher than MVD in the
neoplastic follicles and reactive follicles, but lower than the MVD
of the paracortex of reactive lymphoid tissues. MVD instead was
similar in diffuse large cell lymphomas and in the paracortex of
follicular lymphomas (Table 2).
In five cases of follicular lymphoma, an area of diffuse
transformation was present. The average score for MVD in these
areas was 110, broadly similar to that observed in the diffuse large
B-cell lymphomas. Owing to the small number of cases (only five)
no statistical analysis was attempted.
LH39 staining
In reactive lymphoid tissues the staining with LH39 not only
demonstrates the presence of positivity in the basal membrane of
vessels and lymphatics, but also highlights an LH39 meshwork
present throughout the tissue. Both vessels and lymphatics are
within this meshwork. Regression of this meshwork is present in
the germinal centres. In lymph nodes the meshwork terminates at
the capsule while in tonsil, where the lymphatic tissue is
extranodal, no discrete boundaries are present.
In follicular lymphomas the LH39 meshwork is similar to that
seen in reactive tissue. As in reactive germinal centres, regression
of this meshwork is seen within the neoplastic follicles (Figure 1A,
B). The LH39 meshwork is also not present in both large B-cell
lymphomas and the focal large cell lymphoma transformations
seen in five follicular lymphomas (Figure 1C).
Vascular phenotype
In Tables 1 and 2, the data concerning the vascular phenotype in
reactive lymphoid tissue (tonsil and lymph node) and lymphomas
are summarised.
Table 1 Comparison of MVD, number of mature vessels (LH39+) and
putative immature vessels (aVb3+) between follicles and paracortex in
reactive hyperplasia and follicular lymphomas (paired samples t-test)
Follicles Paracortex P-value
Reactive, nodes and tonsils (17)
MVD 68.7 vs 282.5 o0.0009
LH39+vessels 77.8 vs 97.7 o0.0009
aVb3+vessels 10.2 vs 22.6 =0.044
Follicular lymphoma, All (23)
MVD 65.9 vs 184.6 o0.0009
LH39+vessels 75.8 vs 90.4 o0.0009
aVb3+vessels 45.8 vs 66.1 =0.006
Table 2 Comparison of MVD, number of mature vessels (LH39+) and putative immature vessels (aVb3+) between reactive lymphoid tissue, follicular
lymphomas and diffuse large B-cell lymphomas (independent samples t-test)
Follicles
reactive
Follicles follicular
NHL P-value
Paracortex
reactive
Paracortex
follicular NHL P-value
MVD 68.7 vs 65.9 =0.785 282.5 vs 184.6 o0.0009
LH39+vessels 77.8 vs 75.8 =0.689 97.7 vs 90.4 =0.007
aVb3+vessels 10.2 vs 45.8 o0.0009 22.6 vs 66.1 o0.0009
Diffuse
B NHL
Follicles
reactive P-value
Diffuse
B NHL
Paracortex
reactive P-value
MVD 185.7 vs 68.7 o0.0009 185.7 vs 282.5 =0.001
LH39+vessels 50.8 vs 77.8 =0.007 50.8 vs 97.7 o0.0009
aVb3+vessels 62.7 vs 10.2 o0.0009 62.7 vs 22.6 o0.0009
Diffuse
NHL
Follicles
follicular NHL P-value
Diffuse
B NHL
Paracortex
follicular NHL P-value
MVD 185.7 vs 65.9 o0.0009 185.7 vs 184.6 =0.956
LH39+vessels 50.8 vs 75.8 =0.007 50.8 vs 90.4 o0.0009
aVb3+vessels 62.7 vs 45.8 =0.019 62.7 vs 66.1 =0.637
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In the paracortex of the reactive lymph nodes, all the vessels
were LH39 positive and were associated with the LH39 meshwork
(Figure 1D): LH39-negative vessels could not be detected. In
reactive tonsils some LH39-negative vessels were present on the
edge of the lymphoid tissue and they accounted for 7.8% of the
paracortical vessels. The paracortex of follicular lymphoma nodes
differed from the paracortex of reactive nodes as some LH39-
negative vessels were seen in the former (Figure 1F). Also, the
number of aVb3-positive vessels was different as less aVb3-
positive vessels were seen in the paracortex of the reactive tissue
(Table 2).
Reactive follicles contained instead some LH39-negative vessels
(Figure 1E) and the same results were found in neoplastic follicles
(Figure 1G). Both in reactive and neoplastic follicles the proportion
of mature LH39-positive vessels was the same (Table 2). However,
the number of vessels positive for aVb3 was lower in reactive than
in neoplastic follicles.
The proportion of LH39-positive vessels within the large cell
lymphomas was lower than that observed in reactive tissue and
follicular lymphoma (both in follicles and paracortex). The
number of aVb3 vessels was instead comparable to that seen in
follicular lymphomas (follicles and paracortex) and was higher
than the number of aVb3-positive vessels seen in reactive tissue
(follicles and paracortex) (Table 2).
Vascular regression
Results of the scoring for vascular regression are shown in Tables 3
and 4. Examples of the vessels scored as regressing are shown in
Figure 1H–K. The percentage of regressing vessels was higher in
follicles (reactive and neoplastic) than in the paracortex (Table 3).
Table 4 shows that the same high proportion of regressing vessels
was present in reactive and neoplastic germinal centres, while only
occasional regressing vessels were present, in a similar fashion, in
large cell lymphomas and in paracortical areas.
DISCUSSION
The discrepancies in previous studies (Veiga et al, 1998; Hyjek
et al, 1999; Ribatti et al, 1999; Vacca et al, 1999b; Arias and Soares,
2000; Ridell and Norrby, 2001) concerning MVD values in reactive
Figure 1 Vascular phenotype in reactive and neoplastic lymph nodes. LH39-positive meshwork in (A) a reactive lymph node (B) a follicular lymphoma
and (C) a large B-cell lymphoma; in the latter only a few residual fragments of the LH39 meshwork are present (arrow). (D) Reactive lymph nodes: all the
vessels in the paracortex are within the LH39 meshwork while (E) LH39-negative vessels are present within a germinal centre. (F) Only rare LH39-negative
vessels are seen in the paracortex in Follicular lymphomas (arrow) while (G) some more are present in the neoplastic follicles (arrows). Sequence of vascular
regression: (H) A normal vessel in which the endothelial cells and the LH39-positive basal membrane are superimposed. (I) early detachment of the
endothelial cells from the basal membrane. (J,K) Progressive fragmentation of both endothelial cells and basal membrane leading to vascular regression.
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lymphoid tissues and lymphomas were the primary issue for this
investigation. Our data confirm that both in reactive lymph nodes
and in lymph nodes with follicular lymphomas, the MVD is higher
in the paracortex than in the follicles and that there is no difference
in MVD between reactive germinal centres and neoplastic follicles.
Finally, it was shown that MVD in the paracortex in reactive nodes
is higher than in the paracortex of follicular lymphomas and is also
higher than in diffuse large cell lymphomas. This is of interest
because of the general consensus that angiogenesis is higher in
cancer than in non-neoplastic tissues. However, it is reasonable to
think that in the reactive nodes physiologic angiogenesis is more
effective than the tumour-induced one.
Therefore, we did not confirm the data suggesting that MVD in
lymphomas is higher than in reactive lymphoid tissue (Ribatti et al,
1996; Vacca et al, 1999b).
The follicular component of follicular lymphomas has an MVD
lower than large B-cell lymphomas. However, a number of
neoplastic cells in follicular lymphomas are also present in the
paracortex where the MVD is comparable to that of large cell
lymphomas, suggesting that MVD alone is unlikely to be dictating
the aggressiveness of the lymphoma. This finding also suggests
that the neoplastic cells colonizing the paracortex might exploit the
existing vessels in the same way that we and others (Miliaras et al,
1995; Guidi et al, 2000; Pezzella et al, 2000; Naresh et al, 2001) have
suggested for solid tumors in reactive nodes.
Our study also revealed a previously unknown anatomical
characteristic of the lymph node, that is, an extracellular mesh-
work identified by the expression of LH39. Within this meshwork,
in reactive node, are contained all the vessels. When a reactive
germinal centre develops, lysis of this meshwork and vascular
regression occurs. This meshwork is also present in extranodal
lymphatic tissue, that is, tonsil. As this organ has no discrete
boundaries (i.e. a capsule) newly formed LH39 vessels are
observed at the edge, probably recruited from the surrounding
stroma.
The observation of vascular regression in the germinal centre,
associated with neoangiogenesis is the second novel finding. Active
vascular remodelling and angiogenesis in adult normal tissues
were until now thought to be limited to endometrium, ovary and
breast, under the control of cyclic hormonal changes (Augustin,
2000). The occurrence of physiological vascular regression and
neoangiogenesis in germinal centres makes it a valuable place to
study the pathways regulating normal vascular remodelling (e.g.
the angiopoietin pathway) (Holash et al, 1999). Furthermore, it
also suggests that this could be one of the mechanisms of growth
control that alongside others, like the lack of bcl-2, limits the
expansion of germinal centre cells. It needs also to be clarified how
the vascular regression is regulated and whether apoptosis plays a
role in it.
This situation described in reactive nodes is maintained in
follicular lymphomas as summarised from the literature (Stewart
et al, 2002) (Doussis-Anagnostopoulou et al, 1997) in Table 5 with
only three differences: a higher expression of aVb3, the presence in
the paracortex of a few immature (LH39-negative) vessels and the
expression of VEGF on the neoplastic cells. The observations by
Hyjek et al (1999) that mostly mature vessels are present in
follicular lymphomas and that the same overall vascular distribu-
tion is seen in follicular lymphoma and reactive nodes could be
explained by the fact that a similar angiogenic pathway might be
activated in both of these conditions. However, our data showing a
difference, small but significant, in LH39-negative and aVb3-
positive vessels suggest that in the paracortex of follicular
lymphomas a second angiogenic pathway is appearing.
A different situation is found in large B-cell lymphomas:
regression of the LH39 meshwork occurs while only occasional
regressing vessels are seen. This finding supports the hypothesis
that in follicular lymphoma the neoplastic cells retain the ability to
balance neoangiogenesis with vascular regression. This character-
istic is lost in large cell lymphoma and could be another factor
contributing to their aggressiveness.
Secondly, although large cell lymphomas have a lower MVD
than the reactive paracortex, the phenotype of the vessels is
different. Half of them are immature (LH39-negative) and aVb3 is
widely expressed. These data indicate that the angiogenic pathway
producing immature vessels becomes predominant during the
progression from follicular to diffuse lymphoma. Furthermore, the
balance between neoangiogenesis and vascular regression, still
maintained in neoplastic follicles, is lost in diffuse large cell
lymphomas. Large B-cell lymphomas therefore have a vascular
Table 4 Comparison of percentage of regressing vessels between reactive lymphoid tissue, follicular lymphomas and diffuse large B-cell lymphomas
(independent samples t-test)
Follicles
reactive
Follicles
follicular NHL P-value
Paracortex
reactive
Paracortex
follicular NHL P-value
Regressing vessels (%) 10.4 vs 10.1 =0.940 2.1 vs 0.2 =0.223
Diffuse
NHL
Follicles
reactive P-value
Paracortex
reactive
Diffuse
B NHL P-value B
Regressing vessels (%) 0.4 vs 10.4 =0.001 2.1 vs 0.46 =0.286
Diffuse
NHL
Follicles
follicular NHL P-value
Diffuse
B NHL
Paracortex
follicular NHL P-value
Regressing vessels (%) 0.4 vs 10.1 o0.0009 0.4 vs 0.2 =0.469
Table 3 Comparison of percentage of regressing vessels between
follicles and paracortex in reactive hyperplasia and follicular lymphomas
(paired samples t-test)
Follicles %
regressing
vessels
Paracortex %
regressing
vessels P-value
Reactive, nodes only (11) 9.0 vs 0.2 =0.021
Reactive, nodes and tonsils (16) 10.4 vs 2.1a =0.010
Follicular NHL all (21) 10.1 vs 0.2 o0.0009
aThe high value reported in the paracortex of reactive tonsils is because of a single
case of reactive tonsil in which 24% of the paracortical vessels showed signs of
regression.
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phenotype comparable to that observed in solid tumours
(Kakolyris et al, 1999, 2000; Passalidou et al, 2002).
Lymphatic vessels have not been investigated in this study.
Efforts have been made to exclude them on morphological
examination but the recent identification of the molecule Lyve 1
and the raising of a specific antibody against this protein (Skobe
et al, 2001), which is specifically expressed on lymphatic vessels,
will allow this to be properly investigated in normal and neoplastic
lymph nodes in future studies.
The heterogeneous patterns of vascularity observed in this study
suggest that different types of approach may be needed to exploit
anti-angiogenic treatment in lymphomas. In follicular lymphomas,
where vessels are mostly mature but with aVb3 expression, the
humanised anti-aVb3 antibody Vitaxin (Gutheil et al, 2000) might
be suitable. In contrast, antiangiogenic drugs interacting with the
formation of new vessels may be more effective in diffuse large B-
cell lymphomas.
In conclusion, our data support the hypothesis that follicular
lymphomas grow in a fashion very similar to that of reactive lymph
nodes while large B-cell lymphomas have angiogenic patterns
similar to that seen in many epithelial tumors.
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